Detailed Information on Publication Record
2005
Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease.
MAYER, Jiří, Marta KREJČÍ, M. DOUBEK, Z. POSPÍŠIL, Yvona BRYCHTOVÁ et. al.Basic information
Original name
Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease.
Name in Czech
Puls cyklofosfamidu na kortikoid-rezistentní GVHD.
Authors
MAYER, Jiří, Marta KREJČÍ, M. DOUBEK, Z. POSPÍŠIL, Yvona BRYCHTOVÁ, Miroslav TOMIŠKA and Zdeněk RÁČIL
Edition
Bone Marrow Transplantation, London, Nature publishing group, 2005, 0268-3369
Other information
Type of outcome
Článek v odborném periodiku
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 2.643
Organization unit
Faculty of Medicine
UT WoS
000227827100009
Keywords (in Czech)
akutní GVHD, cyklofosfamid, imunosuprese
Keywords in English
acute GVHD; cyclophosphamide; immunosuppression
Změněno: 3/11/2010 15:13, prof. MUDr. Zdeněk Ráčil, Ph.D.
Abstract
V originále
Corticosteroid-resistant GVHD is difficult to manage and is associated with high morbidity and mortality. Cyclophosphamide (Cy) is an established immunosuppressive and cytotoxic drug widely used as part of pretransplant conditioning regimens. In a retrospective study of 15 patients who had not responded to corticosteroids (nine with acute GVHD, three with GVHD after donor leukocyte infusion, and three progressive chronic GVHD), pulse Cy at a median dose of 1 g/m(2) was very effective in the treatment of skin (100% response), liver (70% response), and the oral cavity (100% response). Severe intestinal GVHD responded poorly. The toxicity pro. le was acceptable, with manageable, short-term myelosuppression in some patients. The risk of opportunistic infections, mixed chimerism, relapses, or post-transplant lymphoproliferative disease was not increased. Overall survival was 57%, with median and maximum follow-up of 9 and 37 months, respectively. The cost of the drug was negligible, especially when compared to monoclonal antibodies. Pulse Cy requires further investigation in corticosteroid-resistant GVHD.